Last reviewed · How we verify

Ocuwize LTD — Portfolio Competitive Intelligence Brief

Ocuwize LTD pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
LO2A eye drops LO2A eye drops marketed Prostaglandin analog Prostaglandin F (FP) receptor Ophthalmology
Systane Ultra UD Systane Ultra UD marketed Artificial tear / Ocular lubricant Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 2 shared drug classes
  2. AbbVie · 2 shared drug classes
  3. Bausch & Lomb Incorporated · 1 shared drug class
  4. Aultman Health Foundation · 1 shared drug class
  5. Bp Consulting, Inc · 1 shared drug class
  6. Bnai Zion Medical Center · 1 shared drug class
  7. Andover Research Eye Institute · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ocuwize LTD:

Cite this brief

Drug Landscape (2026). Ocuwize LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ocuwize-ltd. Accessed 2026-05-13.

Related